Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection
Condition(s) studied
Investigational drug(s) / intervention(s)
Conventional treatment: Beside the using of Sivelestat Sodium or placebo, all postoperative care will adhere to each center's standard protocols for type A aortic dissection.
Sivelestat sodium: The daily dose (4.8 mg/kg) is diluted in 48 mL of 0.9 % saline and administered as a continuous intravenous infusion over 24 hours at 2 mL/h (equivalent to 0.2 mg/kg/h) for 72 consecutive hours.
Placebo: An equal volume of placebo-containing only the excipients of sivelestat sodium and diluted to 48 mL with 0.9 % saline-will be infused at 2 mL/h for 72 consecutive hours.
Study summary
The goal of this multicenter, double-blind, randomized controlled trial is to learn if sivelestat sodium (Siv) can protect the organ function in patients suffered operation for acute type A aortic dissection. The main questions it aims to answer are:
* Can the 3-day-treatment of Siv enlarge the Day-0-to-Day-5 drop in the organ-health score (SOFA score)?
* Can this treatment significantly shrink the area under the SOFA curve from first dose to Day 5?
* Can this treatment significantly improve the end of patients in 28 days (clinical outcomes)? Researchers will compare drug Siv to a placebo (a look-alike substance that contains no drug) to see if drug Siv works.
Participants will:
* Take drug Siv or the placebo through vein continuously for 72 hours
* Receiving regular intensive care in ICU after the operation
Eligibility
Primary outcome measure(s)
- ΔSOFA5 — from the entry of ICU(baseline, post-operatively) to the fifth day in ICU(the fifth day after the first dose)
ΔSOFA5 is defined as the decrease level of SOFA(Sequential Organ Failure Assessment) score from baseline to the fifth day. SOFA score ranges from 0\~24, the higher the score, the poorer the functionality of multiple organs.
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| The First Affiliated Hospital of Anhui Medical University | Hefei | Anhui | |
| Fujian Provincial Hospital | Fuzhou | Fujian | |
| Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) (Guangdong Provincial People's Hospital Affiliated to Southern Medical University) | Guangzhou | Guangdong | |
| The University of Hong Kong - Shenzhen Hospital | Shenzhen | Guangdong | |
| The First Affiliated Hospital of Xi'an Jiao Tong University | Xi'an | Shaanxi | |
| Changhai Hospital of Shanghai | Shanghai | Shanghai Municipality |
More Shanghai Zhongshan Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07156656 on ClinicalTrials.gov ↗ ← All trials in China